A phase II study of eltrombopag in patients with severe aplastic anemia

Trial Profile

A phase II study of eltrombopag in patients with severe aplastic anemia

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2015

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2015 According to Ligand Pharmaceuticals media release, Revolade received EU approval as First-in-class Therapy for patients with severe anaplastic anemia.
    • 30 Jul 2015 New trial record
    • 24 Jul 2015 CHMP recommended this drug for EU approval based upon the results of Phase 2 study (ELT112523) and two supporting Phase 2 studies (ELT116826 and ELT116643).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top